
51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
🔬 Science
💰 $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
🕒 October 7
Where this job comes from
Posted on Kyverna Therapeutics's careers page ↗, not through a job board
First seen by Remote Rocketship October 7
Still open on Kyverna Therapeutics's site. Checked 4 hours ago.

51 - 200 employees
Founded 2019
🧬 Biotechnology
💊 Pharmaceuticals
🔬 Science
💰 $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
• Own the commercial marketing strategy for the company’s CAR-T portfolio across current and future autoimmune indications • Develop and lead the overall marketing strategy and commercial vision • Establish strategic capabilities, infrastructure, and organizational readiness • Define launch objectives, customer priorities, brand positioning, messaging, channel strategy, unbranded education, promotional approach, and measurement • Translate clinical data, market research, competitive intelligence, and customer insights into actionable marketing strategies • Develop understanding of patient journeys, referral ecosystems, treatment pathways, and adoption barriers across autoimmune diseases • Lead the marketing organization through the company’s first product launch and establish a repeatable launch model • Establish launch performance metrics and optimize strategy using market feedback, customer behavior, competitive activity, and emerging data • Develop post-launch strategies and differentiated lifecycle strategies for additional indications, patient populations, and disease settings • Partner with Clinical Development, Medical Affairs, Market Access, Commercial Operations, Sales, Regulatory, and Legal/Compliance • Establish customer and market insights capabilities • Provide commercial perspectives to senior leadership and the executive team • Build and lead a high-performing marketing organization • Determine required capabilities, talent, agency partnerships, and infrastructure • Establish objectives, operating processes, and performance metrics • Develop a culture of accountability, strategic thinking, collaboration, and agile execution
• 15+ years of progressive experience in biopharmaceutical commercial/marketing roles • Significant experience in specialty, rare disease, hematology, immunology, or other complex therapeutic markets • Demonstrated experience personally leading a successful U.S. product launch from pre-launch through commercialization • Experience developing commercialization strategies for innovative therapies, preferably CAR-T, cell therapy, gene therapy, or other highly specialized treatments • Proven experience developing multi-indication and lifecycle strategies for a pharmaceutical or biotechnology asset • Experience building or significantly transforming a marketing organization in a growth-stage or emerging biotech environment • Strong understanding of commercialization, brand strategy, market development, customer segmentation, personal and digital engagement, market research, forecasting, and promotional strategy • Ability to translate complex clinical/scientific data into differentiated commercial positioning • Experience working across Medical Affairs, Clinical Development, Market Access, Regulatory, Sales, and executive leadership • Understanding of treatment, referral, reimbursement, and healthcare-provider ecosystems associated with specialty and cell therapies • Understanding of challenges associated with launching innovative or highly specialized therapies • Exceptional strategic thinking and willingness to personally drive execution • Exceptional communication and executive presence • Ability to influence senior leadership and cross-functional stakeholders • Ability to operate effectively in a fast-paced, entrepreneurial environment with evolving priorities
• Bonus eligibility • Benefits • Participation in Company’s stock plan • Remote work arrangement • Approximately 25–40% travel
Apply NowImprove your chances of getting an interview by checking your resume score before you apply.
🕒 October 7
Vice President leading pricing, reimbursement, payer engagement, and commercialization access for SpyGlass Pharma’s ophthalmic drug-delivery therapies. Building the market access organization for Phase 3 and launch growth.
🇺🇸 United States – Remote
💵 $325k - $385k / year
💰 $75M Series D - Spyglass Pharma on 2025-06
⏰ Full Time
🔴 Lead
👔 Vice President
🕒 October 6
Executive leading GPO and corporate account growth for Ocular Therapeutix, an ophthalmic biopharmaceutical company. Building Retina-focused teams, negotiating contracts, and managing strategic provider relationships.
🕒 October 6
Executive leading national patient access, reimbursement, and support strategies for Ocular Therapeutix’s ophthalmic therapies. Building scalable teams and launch-ready infrastructure for Retina products.
🕒 October 6
VP leading market access, HEOR, pricing, and payer engagement for Ocular Therapeutix’s ophthalmic therapies. Shaping coverage, reimbursement, launch readiness, and patient access across the US payer landscape.
🕒 October 6
VP leading Lydian Energy’s utility-scale solar and BESS construction portfolio. Delivering multi-project execution safely, on schedule, on budget, and through COD.